$ 96.74
Key Takeaways
Risk factor
Very high price volatility
Profitability factor
Strong margins and returns
About
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat...
Company Valuation
Considering past and projected metrics, the stock is neither 'expensive' nor 'cheap' compared to its peers. Specifically, the stock is neutral on EV/EBITDA, underpriced o
Target Price
The average target price of BNTX is 132 and suggests 37% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increas
